Jump to content

Vericel

From Wikipedia, the free encyclopedia
(Redirected from Aastrom Biosciences)
Vericel Corporation
FormerlyAastrom Biosciences, Inc.
Company typePublic
NasdaqVCEL
Russell 2000 component
S&P 600 component
IndustryBiotechnology
Founded1989; 35 years ago (1989) in Ann Arbor, Michigan, United States
Headquarters,
United States
Number of locations
2
Key people
  • Nick Colangelo (CEO)
  • Daniel Orlando (COO)
  • Gerard Michel (CFO)
Products
  • MACI
  • Epicel
  • Carticel

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.[1]

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011.[1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.[1]

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.[1]

References

[edit]
  1. ^ a b c d Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.